文献速递乳腺癌放疗姑息放疗与转移瘤放疗物理与技术

18F-FDG-PET/CT引导SBRT联合CDK4/6抑制剂治疗晚期乳腺癌

18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Guided Stereotactic Body Radiation Therapy in Advanced Breast Cancer Patients Treated WithCyclin-Dependent Kinase 4/6 Inhibitors.
PubMed 文献 · Adv Radiat Oncol · 2026-04-07

这项回顾性研究纳入29例接受18F-FDG-PET/CT监测的晚期乳腺癌患者,评估PET/CT引导立体定向体部放疗(SBRT)联合CDK4/6抑制剂的安全性、可行性和疗效。

要点

  • 单次SBRT后mCR率高于大分割SBRT(P=.03)
  • 较小病灶(<14 cm3)和较低SUVmax(<6.3)与mCR相关
  • 中位无进展生存期48.2个月,2年PFS率71.5%

核心结论

  • 18F-FDG-PET/CT引导SBRT联合CDK4/6抑制剂可使晚期乳腺癌患者获得较高代谢完全缓解率,尤以单次SBRT为著。

研究设计与样本

  • 回顾性研究,纳入29例接受18F-FDG-PET/CT监测并接受SBRT联合CDK4/6抑制剂治疗的晚期乳腺癌患者,中位年龄61岁(IQR 53-68)。

主要发现

  • 除1个病灶外,所有病灶SBRT后SUVmax均下降;33个病灶(56%)达到代谢完全缓解(mCR)。
  • mCR在单次SBRT后比大分割SBRT后更常见(P=.03),在较小病灶(<14 cm3,P=.002)和较低SUVmax(<6.3,P=.008)中更常见。
  • SUVmax每增加1个单位,mCR的 odds 降低约18%(OR=0.824,P=.04)。
  • 中位无进展生存期为48.2个月,2年无进展生存率为71.5%(95%CI 50.9-84.6)。

关键数值与推荐

  • mCR在单次SBRT后比大分割SBRT后更常见(P=.03)。
  • mCR在病灶<14 cm3者中更常见(P=.002),在SUVmax<6.3者中更常见(P=.008)。
  • SUVmax每增加1个单位,mCR的OR=0.824(P=.04)。
  • 2年无进展生存率为71.5%(95%CI 50.9-84.6)。

临床怎么用

  • 对于CDK4/6抑制剂治疗的晚期乳腺癌患者,可考虑应用18F-FDG-PET/CT引导SBRT,尤其单次SBRT可能提高代谢完全缓解率。

局限性

  • 回顾性研究,样本量较小(29例),是否延迟疾病进展需更大样本的随机研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cyclin-dependent kinase (CDK) 4/6 inhibitors have transformed the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, yet resistance remains common. Metabolic response assessed by fluorine 18-labeled deoxyglucose might identify patients at risk of treatment failure earlier than conventional imaging. We evaluated the safety, feasibility, and efficacy of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT)-guided stereotactic body radiation therapy(SBRT) combined with CDK4/6 inhibitors. METHODS AND MATERIALS: This retrospective study included 29 patients monitored with 18F-FDG-PET/CT, who received SBRT concurrently with CDK4/6 inhibitors treatment or before CDK4/6 inhibitors commencement. Median age was 61 years (IQR, 53-68). Ten patients had de novo disease. The median disease-free interval for patients with recurrent disease was 66.9 months (IQR, 34.5-108.5). The majority of patients (72%) were treated in the first-line setting; 11 received ribociclib, 15 received palbociclib, and 3 received abemaciclib. Fifty-nine radiation treatments were delivered to 70 lesions: 41 before or concomitantly with the first CDK4/6 inhibitors cycle and 18 for oligoprogressive disease. Twenty-six treatments used single-fraction SBRT, and 33 used hypofractionated SBRT. RESULTS: Post-SBRT maximum standardized uptake value (SUVmax) reduction was observed in all but one lesion. Metabolic complete response (mCR) occurred in 33 sites (56%), more frequently after single-fraction SBRT than hypofractionated SBRT (P = .03), in smaller lesions (<14 cm3, P = .002), and in lesions with lower SUVmax (<6.3, P = .008). Each unit increase in SUVmax reduced odds of mCR by ∼18% (odds ratio, 0.824; P = .04). Median progression-free survival was 48.2 months; 2-year progression-free survival was 71.5% (95% confidence interval [CI], 50.9-84.6). CONCLUSIONS: 18F-FDG-PET/CT-guided SBRT, particularly single-fraction, added to CDK 4/6 inhibitors, is a valuable treatment modality resulting in substantial rates of mCR. Whether this translates into deferring disease progression requires randomized studies with larger treatment groups. To our knowledge, this study represents the first analysis evaluating 18F-FDG-PET/CT-guided SBRT in combination with CDK4/6 inhibitor-based therapy in patients with metastatic breast cancer.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kubeczko M, Sousa B, Oliveira F, et al. 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Guided Stereotactic Body Radiation Therapy in Advanced Breast Cancer Patients Treated WithCyclin-Dependent Kinase 4/6 Inhibitors. Adv Radiat Oncol. 2026. PMID: 42254818. doi:10.1016/j.adro.2026.102052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。